RU2421457C2 - Новые спиро[имидазолидин-4,3'-индол]-2,2',5(1'н)-трионы для лечения состояний, ассоциированных с ваниллоидным рецептором 1 - Google Patents

Новые спиро[имидазолидин-4,3'-индол]-2,2',5(1'н)-трионы для лечения состояний, ассоциированных с ваниллоидным рецептором 1 Download PDF

Info

Publication number
RU2421457C2
RU2421457C2 RU2008131905/04A RU2008131905A RU2421457C2 RU 2421457 C2 RU2421457 C2 RU 2421457C2 RU 2008131905/04 A RU2008131905/04 A RU 2008131905/04A RU 2008131905 A RU2008131905 A RU 2008131905A RU 2421457 C2 RU2421457 C2 RU 2421457C2
Authority
RU
Russia
Prior art keywords
pain
chronic
indole
compound
prop
Prior art date
Application number
RU2008131905/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008131905A (ru
Inventor
Кармен ЛЬЮНГ (CA)
Кармен ЛЬЮНГ
Мирослав ТОМАШЕВСКИ (CA)
Мирослав Томашевски
Саймон ВУ (CA)
Саймон ВУ
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2421457(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2008131905A publication Critical patent/RU2008131905A/ru
Application granted granted Critical
Publication of RU2421457C2 publication Critical patent/RU2421457C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
RU2008131905/04A 2006-02-07 2007-02-06 Новые спиро[имидазолидин-4,3'-индол]-2,2',5(1'н)-трионы для лечения состояний, ассоциированных с ваниллоидным рецептором 1 RU2421457C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07
US60/771,119 2006-02-07

Publications (2)

Publication Number Publication Date
RU2008131905A RU2008131905A (ru) 2010-03-20
RU2421457C2 true RU2421457C2 (ru) 2011-06-20

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008131905/04A RU2421457C2 (ru) 2006-02-07 2007-02-06 Новые спиро[имидазолидин-4,3'-индол]-2,2',5(1'н)-трионы для лечения состояний, ассоциированных с ваниллоидным рецептором 1

Country Status (21)

Country Link
US (2) US20070185179A1 (https=)
EP (1) EP2013215A4 (https=)
JP (1) JP2009526043A (https=)
KR (1) KR20080094906A (https=)
CN (1) CN101415711A (https=)
AR (1) AR059265A1 (https=)
AU (1) AU2007212786B2 (https=)
BR (1) BRPI0707423A2 (https=)
CA (1) CA2641632A1 (https=)
CL (1) CL2009000523A1 (https=)
IL (1) IL192890A0 (https=)
NO (1) NO20083547L (https=)
NZ (1) NZ571070A (https=)
RU (1) RU2421457C2 (https=)
SA (1) SA07280027B1 (https=)
SG (1) SG169387A1 (https=)
TW (1) TW200801011A (https=)
UA (1) UA93226C2 (https=)
UY (1) UY30132A1 (https=)
WO (1) WO2007091947A2 (https=)
ZA (1) ZA200806407B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781521A4 (en) 2011-10-19 2015-03-04 Kowa Co NEW SPIROINDOLIN COMPOUND AND MEDICAL AGENT THEREFOR
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028906A1 (en) * 1979-11-13 1981-05-20 Imperial Chemical Industries Plc 1'-Substituted-spiro(imidazolidine-4,3'-indoline)-2,2',5-triones, processes for their manufacture and pharmaceutical compositions thereof
EP0066378A1 (en) * 1981-05-12 1982-12-08 Imperial Chemical Industries Plc Pharmaceutical spiro-hydantoin derivatives
RU2002104496A (ru) * 1999-07-21 2003-09-27 Астразенека Аб (Se) Новые соединения
WO2005049601A1 (en) * 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
US7585878B2 (en) 2003-06-12 2009-09-08 Astellas Pharma Inc. Benzamide derivative or salt thereof
US7879866B2 (en) 2004-07-19 2011-02-01 Dorte Xenia Gram Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
WO2007091948A2 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028906A1 (en) * 1979-11-13 1981-05-20 Imperial Chemical Industries Plc 1'-Substituted-spiro(imidazolidine-4,3'-indoline)-2,2',5-triones, processes for their manufacture and pharmaceutical compositions thereof
EP0066378A1 (en) * 1981-05-12 1982-12-08 Imperial Chemical Industries Plc Pharmaceutical spiro-hydantoin derivatives
RU2002104496A (ru) * 1999-07-21 2003-09-27 Астразенека Аб (Se) Новые соединения
WO2005049601A1 (en) * 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)

Also Published As

Publication number Publication date
SA07280027B1 (ar) 2010-11-22
AU2007212786A1 (en) 2007-08-16
AU2007212786A8 (en) 2010-05-06
IL192890A0 (en) 2009-02-11
NZ571070A (en) 2011-07-29
WO2007091947A8 (en) 2008-08-07
AU2007212786B2 (en) 2011-06-02
RU2008131905A (ru) 2010-03-20
EP2013215A2 (en) 2009-01-14
US7868181B2 (en) 2011-01-11
ZA200806407B (en) 2009-04-29
CN101415711A (zh) 2009-04-22
EP2013215A4 (en) 2010-09-08
CL2009000523A1 (es) 2009-07-17
BRPI0707423A2 (pt) 2011-05-03
NO20083547L (no) 2008-11-05
WO2007091947A3 (en) 2007-10-04
SG169387A1 (en) 2011-03-30
KR20080094906A (ko) 2008-10-27
JP2009526043A (ja) 2009-07-16
TW200801011A (en) 2008-01-01
UY30132A1 (es) 2009-07-17
CA2641632A1 (en) 2007-08-16
US20090137650A1 (en) 2009-05-28
AR059265A1 (es) 2008-03-19
WO2007091947A2 (en) 2007-08-16
UA93226C2 (en) 2011-01-25
US20070185179A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
CN110003123B (zh) 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
JP4667384B2 (ja) イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
US20170233341A1 (en) Crystal of pyrrole derivative and method for producing the same
AU2007233035A1 (en) Substituted bicyclic derivative and use thereof
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
CA2659952A1 (en) 8-hydroxyquinoline compounds and methods thereof
WO2018181345A1 (ja) 複素環化合物
EA018369B1 (ru) 2-метил-1-(фенилсульфонил)-4-пиперазин-1-ил-1н-бензимидазол, его применение и содержащая его композиция
KR20210082466A (ko) 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물
WO2015157313A1 (en) Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
RU2421457C2 (ru) Новые спиро[имидазолидин-4,3'-индол]-2,2',5(1'н)-трионы для лечения состояний, ассоциированных с ваниллоидным рецептором 1
BRPI0620410A2 (pt) composto, e, uso dos compostos
EP4680335A1 (en) Urea derivatives for inhibiting nlrp3 and uses thereof
AU2011310078A1 (en) Chromene derivatives
CN112888674A (zh) 多环化合物作为可溶性环氧化物水解酶抑制剂
CN116082259B (zh) 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂
RU2352563C2 (ru) Атропоизомеры производных 3-замещенного-4-арилхинолин-2-она
MX2008009999A (es) Novedosos espiro[imidazolidina-4,3'-indol]-2,2',5(1'4)-triones para tratamiento de condiciones asociadas con receptor 1 vaniloide
RU2818244C2 (ru) Ингибиторы каналов с транзиторным потенциалом на основе оксадиазолов
HK40011041B (en) Modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto
WO2006126938A1 (en) Novel 8-sulfonyl-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
HK40011041A (en) Modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto
HK40052677A (en) Polycyclic compounds as soluble epoxide hydrolase inhibitors
JPH0539221A (ja) 血管新生阻害剤
ZA200206860B (en) Carboxylic acid derivatives as IP antagonists.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120207